search
Back to results

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy (ExCell)

Primary Purpose

Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
StemEx®
Sponsored by
Gamida Cell -Teva Joint Venture Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hematologic Malignancies focused on measuring Tetraethylenepentamine, Umbilical Cord Blood Stem Cell Transplantation, Hematological Malignancies, Acute Lymphoid Leukemia, Subjects with high-risk hematologic malignancies who are candidates for allogeneic stem cell transplantation

Eligibility Criteria

12 Years - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinical diagnosis of AML or ALL: CR2 or subsequent complete remission (CR) or CR1 with high-risk features or relapse with < 10% blasts in BM and no circulating blasts.
  2. Clinical diagnosis of CML: in CP1 (Chronic Phase 1) and resistant or intolerant to Gleevec or in CP2 or subsequent CP or in accelerated phase.
  3. Clinical diagnosis of HD: induction failure or relapse and sensitive to last chemotherapy course.
  4. Clinical diagnosis of NHL induction failure or relapse and sensitive to last chemotherapy course.
  5. Clinical diagnosis of MDS with intermediate 2- or high-risk IPSS score.

Exclusion Criteria:

  1. Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except Hydroxyurea).
  2. HIV positive.
  3. Pregnancy or lactation.
  4. Uncontrolled bacterial, fungal or viral infection.
  5. Subjects with signs and symptoms of active central nervous system (CNS) disease.
  6. Availability of appropriate related and willing stem cell donor, who is HLA-matched at 5 or 6/6 antigens.
  7. Prior allogeneic cell transplant.
  8. Allergy to bovine or to any product, which may interfere with the treatment.
  9. Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor.

Sites / Locations

  • UCLA's Jonsson Comprehensive Cancer Center
  • Children's Hospital of Orange County
  • The Children's Hospital, B115, University of Colorado Health Sciences Center
  • Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
  • Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
  • The Cancer Center at Hackensack University Medical Center
  • Cornell University, Joan & Sanford I. Weill Medical College
  • Steven and Alexandra Cohen Children's Medical Center of New York
  • Mount Sinai Medical Center
  • Case Western Reserve University
  • The Western Pennsylvania Hospital
  • University of Pittsburgh Cancer Institute/UPMC Cancer Centers
  • Texas Transplant Institute
  • University of Virginia, Hematopoietic Stem Cell Transplant Program
  • Medical College of Wisconsin Division of Neoplastic Diseases and Related Disorders
  • Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
  • Szent Laszlo & Szent Istvan Hospital
  • Hebrew University Hospital Ein-Karem, Department of Bone Marrow Transplantation And Cancer Immunotherapy
  • Rambam Medical Center
  • Chaim Sheba Medical Center
  • Ospedale Pedriatrico Bambino Gesù
  • Universita di Roma Tor Vergata
  • Ospedale di Careggi BMT Unit Department of Haematology
  • Hospital Clínico Universitario de Valencia
  • Hospital Universitario La Fe
  • Hospital de la Santa Creu i Sant Pau
  • Hospital Germans Trias i Pujol
  • Hospital General Universitario Gregorio Marañón
  • Hospital Universitario Vall d´Hebrón (Pediatrics)
  • Hospital Universitario Vall d´Hebrón

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

StemEx

Arm Description

Outcomes

Primary Outcome Measures

Overall 100-day mortality

Secondary Outcome Measures

180 day mortality, acute Graft versus Host Disease (GvHD) grades III-IV, engraftment failure
Safety and tolerability measures: The incidence and frequency of adverse experiences, acute toxicity, laboratory data and vital signs follow-up.
Proportion of overall mortality at 1 year
Proportion of overall mortality at 2 years

Full Information

First Posted
May 3, 2007
Last Updated
July 9, 2015
Sponsor
Gamida Cell -Teva Joint Venture Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00469729
Brief Title
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Acronym
ExCell
Official Title
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gamida Cell -Teva Joint Venture Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies. For these patients, it is suggested that StemEx® can improve upon the outcome of transplanting a single, unmanipulated cord blood unit by significantly increasing the number of stem/progenitor cells available to the patient.
Detailed Description
Allogeneic hematopoietic stem cell transplantation is a life-saving procedure for patients with hematologic malignancies; yet wide application of this procedure is limited by the availability of suitably Human Leukocyte Antigen (HLA) - matched donors. Only 30% of patients who could benefit from this procedure have an HLA-matched sibling. The lengthy search for a matched donor may critically delay transplantation. In addition, far fewer patients of racial minorities find suitable HLA-matched donors. Umbilical cord blood (UCB) has been increasingly used as an alternative source of stem cells; however, its use in adults and adolescent patients is limited due to insufficient cell dose required for satisfactory hematopoietic reconstitution. Gamida Cell - Teva Joint Venture Ltd. is engaged in the development of StemEx®, an expanded hematopoietic UCB stem cell graft, as a potential medicinal product for the treatment of cancer and hematological malignancies. The expansion technology enables preferential expansion of hematopoietic stem and early progenitor cells and is based on the findings that copper chelators can regulate the balance between self-renewal and differentiation of stem cells. The multi-national, multi-center Phase II/III clinical study designated to evaluate the safety and efficacy of StemEx® will enroll approximately 100 subjects with high-risk hematologic malignancies who are candidates for allogeneic stem cell transplantation (SCT). This study will evaluate the effect of StemEx® on overall survival as measured by overall 100-day mortality. The study consists of 4 phases: Screening phase includes subjects' clinical assessment and screening tests Conditioning phase includes the myeloablative treatment prior transplantation procedure Transplantation and post-transplant follow-up phase to day 180 Observational phase: survival status follow-up to day 730 (18 months)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes
Keywords
Tetraethylenepentamine, Umbilical Cord Blood Stem Cell Transplantation, Hematological Malignancies, Acute Lymphoid Leukemia, Subjects with high-risk hematologic malignancies who are candidates for allogeneic stem cell transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
StemEx
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
StemEx®
Intervention Description
The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
Primary Outcome Measure Information:
Title
Overall 100-day mortality
Time Frame
100 days
Secondary Outcome Measure Information:
Title
180 day mortality, acute Graft versus Host Disease (GvHD) grades III-IV, engraftment failure
Time Frame
180 days
Title
Safety and tolerability measures: The incidence and frequency of adverse experiences, acute toxicity, laboratory data and vital signs follow-up.
Time Frame
180 days
Title
Proportion of overall mortality at 1 year
Time Frame
One year post transplant
Title
Proportion of overall mortality at 2 years
Time Frame
Two years post transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of AML or ALL: CR2 or subsequent complete remission (CR) or CR1 with high-risk features or relapse with < 10% blasts in BM and no circulating blasts. Clinical diagnosis of CML: in CP1 (Chronic Phase 1) and resistant or intolerant to Gleevec or in CP2 or subsequent CP or in accelerated phase. Clinical diagnosis of HD: induction failure or relapse and sensitive to last chemotherapy course. Clinical diagnosis of NHL induction failure or relapse and sensitive to last chemotherapy course. Clinical diagnosis of MDS with intermediate 2- or high-risk IPSS score. Exclusion Criteria: Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except Hydroxyurea). HIV positive. Pregnancy or lactation. Uncontrolled bacterial, fungal or viral infection. Subjects with signs and symptoms of active central nervous system (CNS) disease. Availability of appropriate related and willing stem cell donor, who is HLA-matched at 5 or 6/6 antigens. Prior allogeneic cell transplant. Allergy to bovine or to any product, which may interfere with the treatment. Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ka Wah Chan, MD
Organizational Affiliation
Texas Transplant Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Scott D Rowley, MD
Organizational Affiliation
The Cancer Center at Hackensack University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mary Territo, MD
Organizational Affiliation
UCLA Oncology Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick Stiff, MD
Organizational Affiliation
Loyola University Cardinal Bernardin Cancer Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Agha Mounzer, MD
Organizational Affiliation
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Entezam Sahovic, MD
Organizational Affiliation
The Western Pennsylvania Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Celia Grosskreutz, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Roger Giller, MD
Organizational Affiliation
The Children's Hospital, B115, University of Colorado Health Sciences Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steven Neudorf, MD
Organizational Affiliation
Children's Hospital of Orange County
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ronit Yerushalmi, MD
Organizational Affiliation
Chaim Sheba Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tsila Zuckerman, MD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christelle Ferra, MD
Organizational Affiliation
Germans Trias i Pujol Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cristina Arbona, MD
Organizational Affiliation
Hospital Clínico Universitario de Valencia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Guillermo Sanz, MD
Organizational Affiliation
Hospital Universitario La Fe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
William Arcese, MD
Organizational Affiliation
Universita di Roma Tor Vergata
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alberto Bosi, MD
Organizational Affiliation
Ospedale di Careggi BMT Unit Department of Haematology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sonali Chaudhury, MD
Organizational Affiliation
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jorge Sierra, MD
Organizational Affiliation
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Igor B. Resnick, MD, PhD
Organizational Affiliation
Department of Bone Marrow Transplantation And Cancer Immunotherapy Hebrew University Hospital Ein-Karem, Jerusalem
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Prof. Franco Locatelli, MD
Organizational Affiliation
Ospedale Pedriatrico Bambino Gesù
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Mi Kwon, MD
Organizational Affiliation
Hospital General Universitario Gregorio Marañón
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Pere Barba, MD
Organizational Affiliation
Hospital Universitario Vall d´Hebrón
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Cristina Diaz de Heredia, MD
Organizational Affiliation
Hospital Universitario Vall d´Hebrón
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Prof. Mary J Laughlin, MD
Organizational Affiliation
Hematopoietic Stem Cell Transplant Program, University of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA's Jonsson Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095-1781
Country
United States
Facility Name
Children's Hospital of Orange County
City
Orange
State/Province
California
ZIP/Postal Code
92868-3874
Country
United States
Facility Name
The Children's Hospital, B115, University of Colorado Health Sciences Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60614
Country
United States
Facility Name
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
The Cancer Center at Hackensack University Medical Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
Cornell University, Joan & Sanford I. Weill Medical College
City
New York
State/Province
New York
ZIP/Postal Code
NY 10065
Country
United States
Facility Name
Steven and Alexandra Cohen Children's Medical Center of New York
City
New York
State/Province
New York
Country
United States
Facility Name
Mount Sinai Medical Center
City
One Gustave L Levy Place, BOX 1410, New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Case Western Reserve University
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
The Western Pennsylvania Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Facility Name
University of Pittsburgh Cancer Institute/UPMC Cancer Centers
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Texas Transplant Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
University of Virginia, Hematopoietic Stem Cell Transplant Program
City
West Complex 1300 Jefferson Park Av, Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Medical College of Wisconsin Division of Neoplastic Diseases and Related Disorders
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Szent Laszlo & Szent Istvan Hospital
City
Budapest
ZIP/Postal Code
1097
Country
Hungary
Facility Name
Hebrew University Hospital Ein-Karem, Department of Bone Marrow Transplantation And Cancer Immunotherapy
City
Jerusalem
ZIP/Postal Code
P.O.B 12000
Country
Israel
Facility Name
Rambam Medical Center
City
PO Box 9602, Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Chaim Sheba Medical Center
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Ospedale Pedriatrico Bambino Gesù
City
Roma
ZIP/Postal Code
00165
Country
Italy
Facility Name
Universita di Roma Tor Vergata
City
via Oxford 81, Roma
ZIP/Postal Code
00133
Country
Italy
Facility Name
Ospedale di Careggi BMT Unit Department of Haematology
City
Viale Morgagni, Florence
ZIP/Postal Code
85 - 50134
Country
Italy
Facility Name
Hospital Clínico Universitario de Valencia
City
Avda. Blasco Ibañez, 17, Valencia
State/Province
Comunidad Valenciana
ZIP/Postal Code
46010
Country
Spain
Facility Name
Hospital Universitario La Fe
City
Av Campanar 21, Valencia
ZIP/Postal Code
46009
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau
City
C/ Sant Antoni Maria Claret, Barselona
ZIP/Postal Code
167 - 08025
Country
Spain
Facility Name
Hospital Germans Trias i Pujol
City
Carretera de Canyet s/n, Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital General Universitario Gregorio Marañón
City
Doctor Esquerdo 46 , Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital Universitario Vall d´Hebrón (Pediatrics)
City
Passeig de la Vall d´Hebrón 119-129, Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Universitario Vall d´Hebrón
City
Passeig de la Vall d´Hebrón 119-129, Barcelona
ZIP/Postal Code
08035
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
11849228
Citation
Peled T, Landau E, Prus E, Treves AJ, Nagler A, Fibach E. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br J Haematol. 2002 Mar;116(3):655-61. doi: 10.1046/j.0007-1048.2001.03316.x. Erratum In: Br J Haematol 2002 May;117(2):485.
Results Reference
background
PubMed Identifier
15183895
Citation
Peled T, Landau E, Mandel J, Glukhman E, Goudsmid NR, Nagler A, Fibach E. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol. 2004 Jun;32(6):547-55. doi: 10.1016/j.exphem.2004.03.002.
Results Reference
background
PubMed Identifier
15160922
Citation
Prus E, Peled T, Fibach E. The effect of tetraethylenepentamine, a synthetic copper chelating polyamine, on expression of CD34 and CD38 antigens on normal and leukemic hematopoietic cells. Leuk Lymphoma. 2004 Mar;45(3):583-9. doi: 10.1080/10428190310001598035.
Results Reference
background
PubMed Identifier
16146887
Citation
Peled T, Mandel J, Goudsmid RN, Landor C, Hasson N, Harati D, Austin M, Hasson A, Fibach E, Shpall EJ, Nagler A. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy. 2004;6(4):344-55. doi: 10.1080/14653240410004916.
Results Reference
background
PubMed Identifier
16219531
Citation
Peled T, Glukhman E, Hasson N, Adi S, Assor H, Yudin D, Landor C, Mandel J, Landau E, Prus E, Nagler A, Fibach E. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol. 2005 Oct;33(10):1092-100. doi: 10.1016/j.exphem.2005.06.015.
Results Reference
background
Citation
Shpall EJ, M.d.L., K. Chan, R. Champlin, A. Gee, P. Thall, K. Komanduri, D. Couriel, C. Hosing, B. Andersson, R. Jones, S. Giralt, S. Karandish, T. Sadeghi, B. Muriera, S. O'Connor, L. Wooten, X. Wang, S. Robinson, P. Fu, J. Wilson, T. Peled, F. Grynspan, A. Nagler, J. McMannis; A Phase I/II Study of Ex Vivo Expanded Cord Blood for Leukemia and Lymphoma. ISCT 2005 - conference publication, 2005.
Results Reference
background
PubMed Identifier
18209724
Citation
de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May;41(9):771-8. doi: 10.1038/sj.bmt.1705979. Epub 2008 Jan 21.
Results Reference
background
PubMed Identifier
29477778
Citation
Stiff PJ, Montesinos P, Peled T, Landau E, Goudsmid NR, Mandel J, Hasson N, Olesinski E, Glukhman E, Snyder DA, Cohen EG, Kidron OS, Bracha D, Harati D, Ben-Abu K, Freind E, Freedman LS, Cohen YC, Olmer L, Barishev R, Rocha V, Gluckman E, Horowitz MM, Eapen M, Nagler A, Sanz G. Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant. 2018 Jul;24(7):1463-1470. doi: 10.1016/j.bbmt.2018.02.012. Epub 2018 Mar 1.
Results Reference
derived
Links:
URL
http://www.gamida-cell.com/
Description
Sponsor's website
URL
http://www.lymphomation.org
Description
Patients Against Lymphoma
URL
http://www.bmtinfonet.org/
Description
Bone and Marrow Transplant Information Network
URL
http://www.cancer.gov/cancertopics/types/leukemia
Description
NCI Leukemia Homepage
URL
http://www.medicinenet.com/leukemia/article.htm
Description
Leukemia information on MediciNet.com
URL
http://www.asbmt.org/
Description
American Society for Blood and Marrow Transplantation
URL
http://www.hematology.org/
Description
American Society of Hematology
URL
http://www.lymphoma.org
Description
Lymphoma Research Foundation
URL
http://www.cordbloodforum.org/
Description
Cord Blood Forum
URL
http://www.cibmtr.org/
Description
Center for International Blood and Marrow Transplant Research
URL
http://www.marrow.org/
Description
National Marrow Donor Program
URL
http://www.choc.org/
Description
Children's Hospital of Orange County
URL
http://www.ucdenver.edu/academics/colleges/medicalschool/centers/cancercenter/Pages/CancerCenter.aspx
Description
University of Colorado Cancer Center
URL
http://www.childrensmemorial.org/depts/stemcell/overview.aspx
Description
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital website
URL
http://www.mountsinai.org/
Description
Mount Sinai Medical Center
URL
http://medschool.duke.edu/
Description
Duke University Medical Center
URL
http://www.case.edu/
Description
Case Western Reserve University
URL
http://www.upmccancercenters.com/
Description
University of Pittsburgh Cancer Institute
URL
http://www.mdanderson.org/
Description
MD Anderson Cancer Center
URL
http://www.texastransplant.org/
Description
Texas Transplant Institute
URL
http://www.chu-stlouis.fr/
Description
Hôpital Saint Louis
URL
http://eng.sheba.co.il/
Description
Chaim Sheba Medical Center
URL
http://web.uniroma2.it/home.php?sr=1024
Description
Universita di Roma Tor Vergata
URL
http://www.aou-careggi.toscana.it/internet/index.php
Description
Ospedale di Careggi BMT Unit Department of Haematology
URL
http://www.gencat.net/ics/germanstrias/
Description
Hospital Germans Trias i Pujol
URL
http://www.hospitalclinic.org/
Description
Hospital Clinic of Barcelona
URL
http://www.santpau.es/
Description
Hospital de la Santa Creu i Sant Pau
URL
http://www.ucla.edu/
Description
ULCA

Learn more about this trial

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

We'll reach out to this number within 24 hrs